Support for returning to work after stem cell transplantation
Supportive Care Intervention Development to Address Employment Concerns After Allogeneic Hematopoietic Stem Cell Transplantation
NA · MGH Institute of Health Professions · NCT06494423
This study is testing a program to help people who have had stem cell transplants get back to work and deal with any challenges they face in doing so.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | MGH Institute of Health Professions (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06494423 on ClinicalTrials.gov |
What this trial studies
This feasibility study evaluates a Work Support (WorkS) intervention aimed at helping individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) to address employment challenges as they prepare to return to work. The study will assess the feasibility and acceptability of the WorkS intervention, as well as its preliminary effects on patient-reported outcomes such as return-to-work self-efficacy, work status, quality of life, and financial toxicity. Participants will be recruited from the MGH Cancer Center and will undergo assessments and appointments over a six-month period following their HSCT.
Who should consider this trial
Good fit: Ideal candidates are individuals who have received an allogeneic HSCT within the past six months and have expressed concerns about their ability to return to work.
Not a fit: Patients with acute psychiatric or cognitive conditions that hinder informed consent or compliance with study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the ability of patients to return to work and enhance their overall quality of life post-transplant.
How similar studies have performed: While this approach is novel in the context of HSCT, similar interventions in other populations have shown promise in improving return-to-work outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received an allogeneic HSCT within the past six months to treat a hematological malignancy. * Screen positive for work-related concerns (i.e., responds "yes" to the question, "Are you concerned about your ability to return to work in the coming six months?") Exclusion Criteria: * Patients with acute psychiatric or cognitive conditions which the treating clinician believes prohibits informed consent or compliance with the study procedures * We will not enroll the following special populations: adults unable to consent, individuals not yet adults, pregnant women, and prisoners.
Where this trial is running
Boston, Massachusetts
- MGH Cancer Center — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Kathleen Lyons, ScD, OTR/L — MGH Institute of Health Professions
- Study coordinator: Kathleen Lyons, ScD, OTR/L
- Email: klyons2@mghihp.edu
- Phone: 614-643-5372
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hematopoietic Stem Cell Transplantation, Return to Work